|
The short-chain fatty acid acetate for improving age-associated arterial dysfunction
If you join this study, you will participate in Screening, Baseline, Study Period, and End of Study visits over a ~4-month period. These visits will take about 14 hours of your time total. The study visits will take place at the Division of Renal Diseases and Hypertension Clinical Research... |
|
Acute Equol Supplementation and Vascular Function in Postmenopausal Women with and without CKD
- One screening visit (1.5 hours) and two testing visits (each 5.5 hours) - Testing visits will include a blood draw and non-invasive testing of blood vessel function - All visits will take place at CU Anschutz - As a volunteer, you will receive Blood Lipids Screening; Blood Press... |
|
A Phase 1, Open-Label, Multicenter Study of KYV-101-001, an Autologous Fully-Human Anti-CD19 Chimeric Antigen Receptor T-Cell (CD19 CAR T) Therapy, in Subjects with Refractory Lupus Nephritis
Outpatient CTRC, Renal Research Center, University of Colorado Hospital Apheresis (collection of white blood cells) followed by lymphodepletion (medications to weaken, temporarily, your immune system so that the CAR T cells can grow and work in the body, followed by single infusion of KYV-101 (the CAR T cells made specifically for your body)... |
|
Aquaman: Treatment of Exercise-Induced Pulmonary Vascular Dysfunction After Pulmonary Thromboendoarterectomy
Outpatient CTRC, University of Colorado Hospital This is a 3 month study to see if riociguat improves RHC measurements and exercise tolerance. There are 2 study visits - one at the beginning and one at the end - during which the subject will undergo a 6 MWT as well as a resting RHC and an exercise RHC. Study drug will be uptitrated at we... |
|
Nicotinamide riboside supplementation for treating arterial stiffness and elevated systolic blood pressure in patients with moderate to severe CKD
Renal Research Center, University of Colorado Hospital This is a 3 month study to determine if nicotinamide riboside (a B vitamin) will improve vascular function. During this study labs, vascular function, ambulatory BP, and office BP will be measured before taking the study drug (nicotinamide riboside/placebo) and again 3 months after daily ... |
|
Personalized experiences to inform improved communication for patients with Life Limiting Illness
University of Colorado Hospital For Aim 1, this study will test: 1) the effects on quality of communication between patient and nurse, as measured by the patient, 2) the effect of the intervention on patient’s overall biopsychosocial and spiritual well-being, as measured by the PROMIS 29 profile, and 3) the effects on pa... |
|
Time Restricted Feeding in Autosomal Dominant Polycystic Kidney Disease
Anschutz Health and Wellness, Brain Imaging Center (BIC), Renal Research Center, University of Colorado Hospital We want to study how feasible it is to restrict eating to 8 hours a day. Both groups will participate in a group-based, behavioral dietary intervention for 1 year (initially weekly, then monthly meetings). We will also look at changes in markers in the blood and both the size of the kidn... |
|
Clonal hematopoiesis, mild cognitive impairment and kidney function decline.
Renal Research Center, University of Colorado Hospital CH is a common aging-associated biological state that predisposes to subsequent cardiovascular death, however, whether it plays a role in MCI, dementia and kidney disease progression is unknown and understanding this novel risk factor may uncover new ways to reduce the burden of cognitiv... |
|
A PHASE III, MULTICENTER, SINGLE-ARM STUDY EVALUATING THE EFFICACY, SAFETY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF CROVALIMAB IN
ADULT AND ADOLESCENT PATIENTS WITH ATYPICAL HEMOLYTIC UREMIC SYNDROME (aHUS)
Childrens Hospital Colorado SIngle-arm, uncontrolled, multicenter, global Phase III study designed to evaluate the efficacy, immunogenicity, pharmacokinetics, and pharmacodynamics of crovalimab in patieths with aHUS.... |
|
Inspiratory Muscle Strength Training for Lowering Systolic Blood Pressure in Midlife and Older Adults with Chronic Kidney Disease
Brain Imaging Center (BIC) - Scan Read, University of Colorado Hospital Participants will be instructed in inspiratory muscle strength training (IMST) during baseline and will be evaluated during a 3 month period to see the effects of the device on systolic blood pressure. There will be a "placebo" arm. Participants will not know which arm they are in.... |
|
Effect of Alkali Therapy on Vascular and Graft Function in Kidney Transplant Recipients
Renal Research Center, University of Colorado Hospital Participation will last approximately 52 weeks and will include 3-7 in-person visits. Baseline, Month 6, and Month 12 visits will be held in person to assess blood vessel health. Baseline visits will be coordinated with patients' 1 year post-transplant biopsy. The Month 12 biopsy wil... |
|
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Phase 3 Study to Investigate the Efficacy and Safety of FInerenone, in Addition to Standard of Care, on the Progression of Kidney Disease in Patients with Non-Diabetic Chronic Kidney Disease
Renal Research Center Trial to examine: -the impact of Finerenone vs. Placebo in delaying the progression of kidney disease. -the safety of Finerenone vs. Placebo in addition to standard of care treatment -quality of life measures via survey This trial will include 1580 participants worldwide. Stu... |
|
Feasibility study of empagliflozin in patients with autosomal dominant polycystic kidney disease
Brain Imaging Center (BIC), Brain Imaging Center (BIC) - Scan Read, Renal Research Center, University of Colorado Hospital Participation involves taking the study drug empagliflozin or a placebo for 12 months. Blood sample collection, magnetic resonance imaging (MRI) of the kidneys and blood vessel stiffness testing during visits at baseline, 3-month and 12-month to the Renal Research Clinic located at the... |
|
DiEtary Sodium Intake effects on ertugliflozin-induced changes in GFR, reNal oxygenation and systemic hemodynamics: the DESIGN study, a randomized, placebo-controlled, cross-over study with ertugliflozin in people with type 2 diabetes
Outpatient CTRC, University of Colorado Hospital If you choose to participate, you will take the study medication, ertugliflozin, or placebo over 4 so-called treatment blocks of 20 days each. You will be recommended foods based on a sodium-controlled diet for approximately 23 weeks. There will be 5 study visits total over 23 weeks, which... |
|
A 36-week, single-arm, open-label study to evaluate the safety and tolerability of ferric citrate in children with hyperphosphatemia related to chronic kidney disease.
Childrens Hospital Colorado A single arm trial evaluating efficacy of ferric citrate over 36 weeks in pediatric patients with hyperphosphatemia related to CKD.... |
|
Phenotyping Resting and Exertional Right Ventricular Dysfunction Among Patients with Chronic Obstructive Pulmonary Disease and Pulmonary Artery Enlargement
CTRC Inpatient, Outpatient CTRC, University of Colorado Hospital Study participants will undergo testing to identify patterns of right ventricular dysfunction. If a study participant decides to participate in exercise training, the participant will complete an optional Part 2 of the study. Optional Part 2 includes an exercise training intervention follo... |
|
A multicenter, randomized, double-blind, parallel group, placebo-controlled study to evaluate the efficacy and safety of iptacopan (LNP023) in idiopathic immune complex mediated membranoproliferative glomerulonephritis (IC-MPGN) (G0102598)
Childrens Hospital Colorado, University of Colorado Hospital Assess efficacy and safety of iptacopan compared to placebo and standard of care in adults and adolescents (12-17) with IC-MPGN in native Kidneys... |
|
A Phase 1 study evaluating SC291, a hypoimmune, allogeneic
CD19-directed CAR T cell therapy, in subjects with severe
relapsed or refractory autoimmune diseases (GLEAM)
Outpatient CTRC, Renal Research Center, University of Colorado Hospital Screening and tapering of current immunosuppression therapy for up to 30 days; treatment with lymphodepleting therapy for 3 days followed by one treatment, via infusion, of SC291. Follow-up will be for at least one year. ... |
|
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Ravulizumab in Adult Participants with Immunoglobulin A Nephropathy (IgAN)
Outpatient CTRC, Renal Research Center, University of Colorado Hospital Access to the investigational medication (ravulizumab) will be available to participants following the double-blinded portion of the trial. ... |